Sanofi A/S - leitarniðurstöður

Evrópusambandið - íslenska - EMA (European Medicines Agency)

myozyme

sanofi b.v. - alglucosidasa alfa - glycogen geymsluskammt tegund ii - Önnur meltingarvegi og efnaskipti vörur, - myozyme er ætlað til langtíma ensímuppbótarmeðferðar (ert) hjá sjúklingum með staðfestan greiningu á pompe sjúkdómum (sýru-α-glúkósíðasa skortur). Í sjúklinga með seint-upphaf pompe sjúkdómur sönnun á virkni er takmörkuð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

menquadfi

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - bóluefni - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

dengvaxia

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - fjölmörgum - bóluefni - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. notkun dengvaxia ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vidprevtyn beta

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - bóluefni - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 og 5. 1 in product information document). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.